Galidesivir - Moligand™, 10 mM in Water , CAS No.249503-25-1

CAS: 249503-25-1 Cat. No.: G1498775 Formula: C₁₁H₁₅N₅O₃ Molecular Weight: 265.27 PubChem CID: 10445549

GRADE & PURITY Moligand™, 10 mM in Water

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV , and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC 50 s ranging from ~3 to ~68 μM.

Specifications

Specifications & Purity

Moligand™, 10 mM in Water

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Product Properties

alogp

-2.1

Names and Identifiers

Isomeric SMILES

C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O

Alternate CAS

249503-25-1

PubChem CID

10445549

MeSH Entry Terms

2-(4-amino-5H-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol;BCX-4430;BCX4430;Galidesivir;ImmA cpd;immucillin A;immucillin-A

Molecular Weight

265.27

Application Protocols

No item-specific, validated application protocols are provided in the Product Data for this compound.

General HTS/assay workflow (for guidance only)

• Preparation: equilibrate vial on ice, briefly centrifuge to collect material, open under dry conditions. Dissolve in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM). Aliquot into low-dead-volume tubes.
• Biochemical assays: dilute stock into enzyme buffer to desired concentrations across a multi-point curve (e.g., 10–12 points, 1:3 serial dilution). Include vehicle controls at matched DMSO levels and positive/negative assay controls.
• Cell-based assays: add to prewarmed media; typical final DMSO ≤0.5–1% v/v. Include cytotoxicity counterscreens and orthogonal readouts to detect assay interference.
• Data quality: monitor Z′-factor, S/B, and signal CV. Confirm hits with fresh aliquots and orthogonal assay formats.

Note: Optimize details (incubation time, temperature, cofactors) per your target biology. For regulated studies or GLP workflows, develop and document SOPs tailored to your lab.

Biological Roles

General literature context (non-clinical; for research use only)

• Class: synthetic nucleoside analog structurally related to adenosine.
• Biochemical target area: widely studied in the context of RNA metabolism and viral RNA-dependent RNA polymerase biochemistry, where nucleoside analogs can act as alternative substrates or chain-terminating species in enzymatic assays.
• Mode-of-action perspective: as an adenosine-mimetic, galidesivir can participate in nucleotide recognition events in vitro. Researchers employ it to probe polymerase selectivity, incorporation kinetics, and post-incorporation processing.
• Transport and metabolism (in vitro): nucleoside analogs often require phosphorylation by cellular kinases to form nucleotide triphosphates in cellular systems; enzyme specificity and phosphorylation efficiency are common research endpoints.

Experimental considerations

• Assay design should distinguish direct enzyme effects from cellular uptake/activation limitations; include controls with known adenosine analogs where applicable.
• Analytical monitoring: LC–MS or LC–MS/MS is commonly used to quantify intracellular phosphorylation states in cell-based studies.

Note

• The above describes typical scientific roles of this class of compounds and is provided to guide experimental planning. It does not constitute medical or therapeutic claims.

Buffer Applications

This product is not a buffering reagent and does not form a classical buffer system. However, buffer choice is critical for its use in biochemical assays.

Practical guidance (general)

• Enzymatic assays: use HEPES, Tris, or MOPS buffers at pH 7.0–8.0 depending on enzyme optimum. Include Mg2+ or Mn2+ where polymerase activity requires divalent cations.
• Solvent tolerance: keep DMSO below the enzyme’s tolerated threshold (often ≤1–2% v/v). Match vehicle in controls.
• Stability: maintain neutral pH and avoid strong oxidants; include chelators only if compatible with the enzyme cofactor requirements.

Tips

• Pre-dissolve compound in DMSO, then add to buffer with vigorous mixing to avoid local supersaturation.
• Filter-sterilize assay buffers and use low-binding plastics/glass to minimize adsorption of polar small molecules.

For specific buffer recipes and pH windows validated for your target enzyme, consult the relevant assay literature and optimize empirically.

Green Alternatives

As a screening compound rather than a solvent or auxiliary reagent, “green alternative” considerations focus on handling and formulation rather than replacement.

Best practices to improve sustainability

• Use concentrated DMSO stocks to minimize solvent volumes; dilute into aqueous buffers immediately before use.
• Replace DMF/DMAC with DMSO or water where compatible with assays.
• Implement microscale assays (low-volume plates, e.g., 384/1536-well) to reduce material and solvent consumption.
• Utilize closed, inerted storage (septum vials, crimp caps) to extend shelf life and reduce waste from degradation.

Comparative note (general)

• For nucleoside analogs in HTS, DMSO is often greener than halogenated solvents and offers lower toxicity compared with DMF. Water-based assay buffers provide the greenest matrix when solubility allows.

Conclusion

• No direct “alternative compound” applies, as galidesivir is itself the target test article. Sustainability gains come from solvent selection, assay miniaturization, and robust sample management.

Pharmaceutical Uses

This product is supplied strictly for research use only and is not manufactured to GMP or pharmacopeial specifications. No clinical, diagnostic, or therapeutic uses are supported.

Research formulation context (general)

• Reference material: may be used as a non-GMP reference standard in preclinical assay development, analytical method qualification, and HTS campaigns.
• Stock solutions: DMSO stocks are typical for in vitro testing; for in vivo exploratory work in research animals, vehicle systems are lab-specific and outside the scope of this listing.

Regulatory note

• Not a USP/EP/JPE compendial material. For any regulated application, obtain appropriate-grade material and supporting documentation.

Documentation

• For impurity profiles, residual solvents, and stability indicating methods suitable for research workflows, request the lot-specific CoA. Perform independent verification if results will inform regulated studies.

Physical Properties

Item-specific physico-chemical specifications

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.

General/literature expectations for galidesivir (for context; not item specifications)

• State: typically a solid organic compound (nucleoside analogs are commonly crystalline solids).
• Polarity: high polarity with multiple hydrogen-bonding sites; often readily soluble in polar aprotic solvents (e.g., DMSO) and variably soluble in water depending on form (free base vs. salt).
• Ionization: heteroaromatic base can present weak basicity; overall molecule behaves as a neutral to weakly basic nucleoside analog in aqueous media.
• Partitioning: expected low logP and high polar surface area relative to typical drug-like heteroaromatics.

Handling implications

• Owing to polarity and functionality, material is hygroscopic risk: minimize exposure to ambient moisture; dispense quickly.
• Thermal sensitivity: store at ultra-low temperature to preserve integrity (see Storage & Reconstitution). Avoid repeated warming/cooling.

Important

• Do not treat the above as certificate values. For exact melting point, solubility, refractive index, or pKa applicable to this specific lot, consult the CoA/SDS or perform in-house characterization.

Quality and Grades

Grade for this item

• Moligand™: This designation indicates the compound is provided for small-molecule library and screening applications, emphasizing identity and suitability for biochemical/cellular assay development. It is not a pharmacopoeial grade and is not intended for clinical or diagnostic use.

What this typically entails

• Identity and purity: optimized for research screening; typical controls include structure confirmation (e.g., NMR/MS) and purity by chromatographic methods. Exact purity thresholds and analytics are lot-specific.
• Assay compatibility: intended for high-throughput screening (HTS), fragment screening, or mechanistic enzymology; low non-specific UV background and DMSO compatibility are commonly considered during selection.
• Documentation: CoA provides lot-specific analytical methods, acceptance criteria, and any residual solvent information where applicable.

Item-specific notes

• Purity value and stabilizers: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance and form (solid vs. solution): Not specified for this item; refer to CoA/Spec Sheet.

User guidance

• For structure–activity relationship (SAR) work or orthogonal assays, request CoA and, if needed, additional analytical files (1H/13C NMR, HRMS, HPLC traces). Perform in-house QC upon receipt if your workflow demands verified reference material.

Reaction and Applications

This product is provided as a research-grade small molecule for screening and biochemical studies, not as a general synthetic reagent. Therefore, classical organic reaction applications (e.g., cross-coupling, condensations) are not the primary use case.

Research uses (literature/general context)

• Mechanistic enzymology: employed as a nucleoside analog probe in biochemical assays interrogating nucleotide-processing enzymes (e.g., polymerases) to study binding and incorporation phenomena.
• Cell-based screening: used as a reference compound or test article in phenotypic or target-based assays exploring nucleotide analog activity. Assay setup typically involves DMSO stock preparation and dilution into culture medium/buffer.

Assay development tips

• Prepare fresh DMSO stocks and avoid repeated freeze–thaw; aliquot for single use.
• Include orthogonal readouts (e.g., enzymatic activity vs. reporter signal) to mitigate assay interference.
• Establish solvent controls matching the highest DMSO concentration used.

If you intend to modify this scaffold synthetically, see Synthetic Utility for high-level guidance; however, this catalog item is not positioned as a building block.

Reaction Conditions

Not typically applicable. This catalog item is provided as a research test article, not as a reagent for synthetic transformations; therefore, standard “reaction condition” guidance (catalysts, temperatures, yields) does not apply.

Assay preparation conditions (general guidance for use as a test compound)

• Stock preparation: dissolve in anhydrous DMSO to prepare 10–50 mM stocks. Gentle warming (≤37 °C) and sonication may aid dissolution.
• Working solutions: dilute into assay buffer or cell culture medium to the desired concentration with final DMSO commonly at 0.1–1% v/v.
• Stability: minimize light and heat exposure; prepare fresh dilutions immediately prior to use.

For synthesis-related conditions of galidesivir itself (route development, protecting groups, coupling chemistries), consult the primary literature; such conditions are outside the scope of this product use.

Safety and Handling

GHS and hazard details (item-specific)

• Signal word: Not specified for this item; refer to CoA/Spec Sheet.
• H-statements: Not specified for this item; refer to CoA/Spec Sheet.
• GHS classification/pictograms: Not specified for this item; refer to CoA/Spec Sheet.

General laboratory safety guidance (literature-based and best practices)

• Engineering controls: handle in a chemical fume hood or ventilated enclosure to avoid aerosol or dust exposure.
• PPE: lab coat, safety glasses/goggles, and suitable gloves (e.g., disposable nitrile). For weighed powders, consider double-gloving and using antistatic measures.
• Avoid: inhalation of dust, skin/eye contact, ingestion. Wash thoroughly after handling. Prevent cross-contamination of screening libraries.
• Incompatibilities: strong oxidizers and strong acids/bases may degrade heteroaromatic nucleoside analogs; avoid prolonged exposure to moisture and elevated temperature.
• First aid (overview; defer to SDS):
  • Inhalation: move to fresh air; seek medical attention if symptoms persist.
  • Skin/eye contact: rinse with water for at least 15 minutes; remove contaminated clothing; seek medical advice if irritation persists.
  • Ingestion: rinse mouth; do not induce vomiting unless directed by medical personnel; seek medical attention.
• Fire response: use dry chemical, CO2, or alcohol-resistant foam. Combustion may release nitrogen oxides and carbon oxides.

Always consult the product SDS for authoritative hazard information and emergency procedures.

Solvent Selection

Solubility strategy (general guidance for nucleoside analogs; verify with CoA/your own solubility tests)

• Primary solvent: DMSO is typically the solvent of choice for preparing concentrated stocks (e.g., 10–50 mM) of polar small molecules for screening.
• Aqueous media: Depending on the form (free base vs. salt), galidesivir may dissolve in water or buffer at neutral to slightly acidic pH. Pre-dissolve in a minimal volume of DMSO, then dilute into aqueous assay buffer to desired final DMSO content (often 0.1–1%).
• Alternative solvents: DMF can be used for intermediate solubility. Alcohols (methanol/ethanol) may dissolve limited amounts but can interfere with certain assays.

Polarity and miscibility context (literature/general)

• Polarity class: highly polar, hydrogen-bonding donor/acceptor rich small molecule.
• Expected miscibility: fully miscible with DMSO; limited compatibility with nonpolar solvents (e.g., hexanes, toluene).

Practical tips

• Warm gently (ambient to 37 °C) and vortex/sonicate to aid dissolution; avoid prolonged heating.
• Filter stocks through 0.2 µm PTFE/RC if particulate persists. Confirm concentration by UV or quantitative NMR if critical.

Note: Final solvent choice should be driven by your assay tolerance and compound stability. For exact solubility for this lot, consult the CoA.

Storage and Reconstitution

Item-specific conditions (from Product Data)

• Storage: Store at -80°C.
• Shipping: Dry ice packs + Cold packs.
• Research Use: For research use only.

Best practices

• Upon receipt: keep frozen. If shipped on dry ice, transfer immediately to an ultra-low freezer (-80 °C). Avoid prolonged exposure to ambient temperature during unpacking.
• Aliquoting: under dry, inert conditions if possible. Prepare single-use aliquots to prevent repeated freeze–thaw cycles.
• Thawing: equilibrate on ice; briefly spin down to collect contents before opening.
• Reconstitution: dissolve in anhydrous DMSO to make a concentrated stock. Mix by gentle vortexing/sonication. If aqueous use is required, add DMSO stock slowly into buffer with mixing.
• Working solution stability: keep on ice during use; discard leftover dilutions. For extended storage, freeze aliquots at -80 °C. Avoid frost-free freezers.

Labeling and documentation

• Record concentration, solvent, date of preparation, and lot number on each aliquot. For long-term studies, periodically assess integrity by analytical methods (e.g., HPLC).

For any missing item-specific parameters (appearance, exact solubility, pH stability), refer to the lot-specific CoA/Spec Sheet.

Structure and Identity

Brief overview: Galidesivir (also known in the literature as BCX4430) is a synthetic adenosine-mimetic small molecule commonly used in discovery screening and enzymology studies targeting viral polymerases.

Item-specific identifiers (from Product Data)

• CAS: 249503-25-1
• SKU: G1498775
• Grade: Moligand™
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Literature structural notes (general information; not item specifications)

• Common name/synonym: Galidesivir; BCX4430.
• Core features: adenosine-mimetic C-nucleoside scaffold; fused imidazo[4,5-b]pyridine-like heteroaromatic base covalently linked to a ribose-like carbohydrate moiety.
• Functional groups: multiple heteroatoms (N, O) enabling hydrogen-bond donation/acceptance; polyhydroxylated sugar; neutral/weakly basic heterocycles depending on tautomeric state.
• 2D description: a bicyclic purine-analog base attached to a furanose-like ring via a C–C glycosidic linkage (C-nucleoside), with hydroxyl substituents at sugar positions compatible with nucleoside recognition.

Notes

• Where exact identifiers (InChIKey, SMILES, formula, MW) are required for regulatory or analytical purposes, consult the certificate of analysis (CoA) for this specific lot.

Synthetic Utility

Galidesivir is offered here as a finished small molecule for screening and biochemical research rather than as a synthetic building block. As such, it is not typically employed as a substrate or reagent in general organic synthesis.

Literature perspective on scaffold modification (for medicinal chemistry planning; not specific to this item)

• Nucleoside analog SAR often explores: modifications at the sugar hydroxyl positions, base heteroatom substitution or annulation, and changes to the C–C glycosidic linkage to tune metabolic stability and polymerase recognition.
• Protecting-group strategies: orthogonal acyl/silyl protection of sugar hydroxyls and late-stage heteroaromatic functionalization are common tactics.
• Prodrug approaches: ester or phosphoramidate prodrugs can modulate permeability and intracellular phosphorylation; design and synthesis are specialized and outside the scope of routine bench modifications.

If you intend to derivatize this scaffold, consider procuring dedicated intermediates or building-block analogs rather than modifying this research-grade reference compound.

Target Specificity

Item-specific target, clone, or epitope information is not applicable to this small-molecule product and none is provided in the Product Data.

General literature context

• Nucleoside analogs like galidesivir are often investigated against nucleotide-processing enzymes (e.g., polymerases) in biochemical assays. Any target specificity observed will depend on assay conditions, enzyme source, and metabolic activation state.

For definitive specificity data relevant to your system, consult peer-reviewed literature and generate target-confirmation data in your laboratory.

Frequently Asked Questions

What is Moligand??

Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 249503-25-1, the molecular formula is C11H15N5O3, and the molecular weight is 265.27 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.